NG 350A
Alternative Names: NG-350ALatest Information Update: 16 Apr 2025
At a glance
- Originator PsiOxus Therapeutics
- Developer Akamis Bio; Cancer Research Institute; Parker Institute for Cancer Immunotherapy
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Gene transference; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Carcinoma; Rectal cancer
- No development reported Adenocarcinoma
Most Recent Events
- 03 Apr 2025 Phase-I clinical trials in Rectal cancer (Late-stage disease, Combination therapy) in USA (IV) (NCT06459869)
- 26 Feb 2025 Pharmacodynamic data from preclinical study in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
- 17 Dec 2024 NG 350A licensed to Xuanzhu Biopharma in China